GenFleet Therapeutics 2595.HK
2025 Annual Results







-
-
-





-
-


(KRAS G12V, NSCLC)
TGI
Vehicle, PO, QD
mg/kg RMC-6236, PO, QD 95%
3 mg/kg RMC-6236, PO, QD 106%
mor volume
1200
1000
800
600
400
200


GFH276-EGF
RMC-6236-EGF
Sotorasib-PBS
Sotorasib-EGF
Adagrasib-PBS
Divarasib-PBS
10
100
1000
10000
0.1
1

β

β



cacy		
Grade ≥3 TRAEs		

≥		



达伯特
Fulzerasib Tablets
0.15g×112片/瓶
达伯特®




GENFLEET
THERAPEUTICS
ΣΕLLAS
LIFE SCIENCES GROUP
VERASTEM
ONCOLOGY
Diverse project and platform partnerships

Innovation, in Expedition